Encaleret increased bone turnover markers and improved patient-reported symptoms in people with autosomal dominant hypocalcemia type 1 (ADH1), a genetic form of hypoparathyroidism, in a Phase 3 trial. At 24 weeks, all participants receiving encaleret reported improvement in at least one ADH1 symptom, compared with 46% of those receiving…
Discussion
Over the last 25 years, I’ve spent the majority of my days literally looking up at the sky or the ceiling. My perspective is different from most healthy people since I’ve been lying down somewhere, either on a couch, bed, zero-gravity chair, or one of my beloved hammocks, for decades.
Discussion
The 2026 International Hypoparathyroidism Conference wrapped on Sept. 21. I attended virtually and spent three days hearing about current clinical trials, new standards of care, and the prototype for a home-use calcium tester by Tralyte Health. It was wonderful to have so much information at my fingertips, and…
Discussion
“Don’t lose your grip on the dreams of the past/ You must fight just to keep them alive.” — “Eye of the Tiger” by Survivor Not long ago, I was by the pool, staring at a blank screen and wondering what to write for my next column. I put on…
Get regular updates to your inbox.
